Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Corominas-Faja B, Urruticoechea A, Martin-Castillo B, Menendez JA. Cufí S, et al. Among authors: urruticoechea a. Oncotarget. 2012 Dec;3(12):1600-14. doi: 10.18632/oncotarget.742. Oncotarget. 2012. PMID: 23307622 Free PMC article.
Integrative analysis of a cancer somatic mutome.
Hernández P, Solé X, Valls J, Moreno V, Capellá G, Urruticoechea A, Pujana MA. Hernández P, et al. Among authors: urruticoechea a. Mol Cancer. 2007 Feb 5;6:13. doi: 10.1186/1476-4598-6-13. Mol Cancer. 2007. PMID: 17280605 Free PMC article.
Biological reprogramming in acquired resistance to endocrine therapy of breast cancer.
Aguilar H, Solé X, Bonifaci N, Serra-Musach J, Islam A, López-Bigas N, Méndez-Pertuz M, Beijersbergen RL, Lázaro C, Urruticoechea A, Pujana MA. Aguilar H, et al. Among authors: urruticoechea a. Oncogene. 2010 Nov 11;29(45):6071-83. doi: 10.1038/onc.2010.333. Epub 2010 Aug 16. Oncogene. 2010. PMID: 20711236
A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines.
Puig T, Aguilar H, Cufí S, Oliveras G, Turrado C, Ortega-Gutiérrez S, Benhamú B, López-Rodríguez ML, Urruticoechea A, Colomer R. Puig T, et al. Among authors: urruticoechea a. Breast Cancer Res. 2011;13(6):R131. doi: 10.1186/bcr3077. Epub 2011 Dec 16. Breast Cancer Res. 2011. PMID: 22177475 Free PMC article.
Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
Martin-Castillo B, Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Moreno JM, Corominas-Faja B, Urruticoechea A, Martín ÁG, López-Bonet E, Menendez JA. Martin-Castillo B, et al. Among authors: urruticoechea a. Cell Cycle. 2013 Jan 15;12(2):225-45. doi: 10.4161/cc.23274. Epub 2012 Jan 15. Cell Cycle. 2013. PMID: 23255137 Free PMC article.
FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies.
Martínez-Aranda A, Hernández V, Guney E, Muixí L, Foj R, Baixeras N, Cuadras D, Moreno V, Urruticoechea A, Gil M, Oliva B, Moreno F, González-Suarez E, Vidal N, Andreu X, Seguí MA, Ballester R, Castella E, Sierra A. Martínez-Aranda A, et al. Among authors: urruticoechea a. Oncotarget. 2015 Dec 29;6(42):44254-73. doi: 10.18632/oncotarget.5471. Oncotarget. 2015. PMID: 26497551 Free PMC article.
A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study.
Ocana A, Gil-Martin M, Martín M, Rojo F, Antolín S, Guerrero Á, Trigo JM, Muñoz M, Pandiella A, Diego NG, Bezares S, Caballero R, Carrasco E, Urruticoechea A. Ocana A, et al. Among authors: urruticoechea a. Oncotarget. 2017 Apr 14;8(42):73144-73153. doi: 10.18632/oncotarget.17113. eCollection 2017 Sep 22. Oncotarget. 2017. PMID: 29069857 Free PMC article.
Molecular response to aromatase inhibitor treatment in primary breast cancer.
Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, Drury S, Larionov A, Young O, White S, Miller WR, Evans DB, Dowsett M. Mackay A, et al. Among authors: urruticoechea a. Breast Cancer Res. 2007;9(3):R37. doi: 10.1186/bcr1732. Breast Cancer Res. 2007. PMID: 17555561 Free PMC article. Clinical Trial.
Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.
Saura C, Bendell J, Jerusalem G, Su S, Ru Q, De Buck S, Mills D, Ruquet S, Bosch A, Urruticoechea A, Beck JT, Di Tomaso E, Sternberg DW, Massacesi C, Hirawat S, Dirix L, Baselga J. Saura C, et al. Among authors: urruticoechea a. Clin Cancer Res. 2014 Apr 1;20(7):1935-45. doi: 10.1158/1078-0432.CCR-13-1070. Epub 2014 Jan 27. Clin Cancer Res. 2014. PMID: 24470511 Clinical Trial.
79 results